In a milestone hailed as one of the most significant advances in HIV prevention in decades, the European Union has officially approved lenacapavir, a twice-yearly injectable drug that has shown 100% effectiveness in preventing HIV during clinical trials. Public health experts are calling the approval a “turning point” in the global fight against the virus, which has claimed millions of lives since it was first identified more than 40 years ago.
Unlike traditional daily oral pre-exposure prophylaxis (PrEP), which has proven effective but requires strict adherence, lenacapavir offers protection through just two injections per year. During the recent large-scale trial, none of the participants who received the injection contracted HIV, underscoring the drug’s potential to close prevention gaps caused by missed doses of daily pills.
“This is a paradigm shift,” said Dr. Anne-Marie Schmidt, an infectious disease specialist based in Berlin. “For the first time, we have a prevention method that doesn’t depend on daily behavior. That simplicity could save millions of lives.”
The drug works by blocking a critical protein in the HIV virus, preventing it from replicating inside human cells. Its long-acting design means it remains in the body for months, offering consistent protection with minimal patient intervention.
Despite decades of progress, HIV remains one of the world’s most persistent public health challenges. According to UNAIDS, around 41 million people live with HIV today, and about 31 million are on treatment. In 2024 alone, there were an estimated 1.3 million new infections and 630,000 deaths from AIDS-related illnesses.
The virus continues to disproportionately impact marginalized groups, including men who have sex with men, sex workers, people who inject drugs, and communities in sub-Saharan Africa. For many, social stigma, lack of healthcare access, and structural inequalities create barriers to prevention and treatment. Experts believe lenacapavir’s simple dosing schedule could overcome some of these barriers, especially in communities where daily medication is impractical.
Health organizations across Europe and beyond have welcomed the EU’s approval, but they are also urging swift action to ensure equitable global access. The history of HIV treatment has shown that life-saving drugs often reach wealthy nations first, leaving low- and middle-income countries struggling for years to gain access.
“We cannot afford to repeat past mistakes,” said a spokesperson for the Global Network of People Living with HIV. “This breakthrough must be accessible and affordable to everyone, not just those in high-income countries.”
The manufacturer, Gilead Sciences, has pledged to work with global health agencies to expand access. Still, pricing remains a key concern, as injectable therapies are often expensive. Advocates are calling for licensing agreements, subsidies, and international cooperation to make the drug available in regions hardest hit by HIV.
The approval of lenacapavir is being hailed as a major step toward achieving the United Nations’ goal of ending AIDS as a public health threat by 2030. While antiretroviral therapy has turned HIV into a manageable condition for millions, prevention remains critical to reducing new infections.
“This is the kind of innovation that moves us closer to a world without AIDS,” said UNAIDS Executive Director Winnie Byanyima in a statement responding to the EU’s decision. “But innovation alone will not be enough. We must match scientific progress with political will and global solidarity.”
If widely adopted, lenacapavir could significantly reduce the number of new HIV cases worldwide, particularly in areas with high infection rates and limited healthcare infrastructure. Experts say the medication also has the potential to reduce healthcare costs in the long term by preventing infections and lowering the need for lifelong treatment.
Attention now turns to regulatory bodies in North America, Africa, and Asia, where approval could accelerate access for millions more. The United States Food and Drug Administration (FDA) and the World Health Organization (WHO) are expected to closely examine the EU’s findings as they consider their own recommendations.
In communities hardest hit by HIV, the hope is palpable. For many, lenacapavir represents more than just a medical innovation—it symbolizes progress toward a future free from the shadow of HIV/AIDS.
As the world watches this historic development unfold, the challenge will be ensuring that this groundbreaking tool is not only celebrated but also shared equitably. Science has once again delivered hope; it is now up to governments, institutions, and communities to transform that hope into global impact.
About the Author
